| Prev Close: | 29.16 |
|---|---|
| Open: | 29.13 |
| Bid: | 29.29 x 2000 |
| Ask: | 29.34 x 300 |
| 1y Target Est: | 31.07 |
| Beta: | 0.74 |
| Next Earnings Date: | 29-Jul-13 |
| Day's Range: | 29.03 - 29.45 |
|---|---|
| 52wk Range: | 22.00 - 31.15 |
| Volume: | 160,346,473 |
| Avg Vol (3m): | 44,343,400 |
| Market Cap: | 208.54B |
| P/E (ttm): | 14.07 |
| EPS (ttm): | 2.09 |
| Div & Yield: | 0.96 (3.30%) |
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Pfizer Obtains $2.15 Billion Settlement from Teva and Sun for Infringement of Protonix® Patentat noodls(Wed 12 Jun)
- Merck & Co., Inc. and Pfizer Enter Worldwide Collaboration Agreement to Develop and Commercialize Ertugliflozin, an Investigational Medicine for Type 2 Diabetesat noodls(Tue 30 Apr)
- Pfizer Presents Phase 3 Safety And Immunogenicity Data On Prevenar 13 In Adults Aged 18 To 49 Yearsat noodls(Mon 29 Apr)
- Pain Therapeutics Reports Q1 2013 Financial Resultsat noodls(Thu 25 Apr)
- Pfizer’s BOSULIF® (bosutinib) Receives Conditional Marketing Authorization From The European Commissionat noodls(Thu 28 Mar)
- XELJANZ® (tofacitinib citrate) Approved in Japan for the Treatment of Adults with Rheumatoid Arthritis (RA)Business Wire(Mon 25 Mar)
- Lpath Granted Key European and U.S. Patents Related to Anti-Cancer Drug Program, ASONEPat noodls(Fri 22 Mar)
- UPLYSO(TM) (alfataliglicerase) Approved in Brazil by ANVISA for the Treatment of Gaucher Diseaseat noodls(Tue 19 Mar)
- ELIQUIS® (apixaban) Approved In Japan For The Prevention Of Stroke And Systemic Embolism In Patients With Nonvalvular Atrial FibrillationBusiness Wire(Wed 26 Dec)
- PropThink: Big Catalysts Approaching For Trius TherapeuticsACN Newswire(Thu 8 Nov)
- Agilent Unit & Pfizer CollaborateZacks(Fri 15 Feb)
- Data on Biogen Hemophilia CandidatesZacks(Tue 12 Feb)
- The Zacks Analyst Blog Highlights: Comstock Resources, Pfizer, Actavis, Sanofi and Novo NordiskZacks(Sat 9 Feb)
- Protalix Exploring OptionsZacks(Fri 8 Feb)
- Data on Auxilium's XiaflexZacks(Fri 8 Feb)
Press Releases
- XELJANZ® (tofacitinib citrate) Approved in Japan for the Treatment of Adults with Rheumatoid Arthritis (RA)Business Wire(Mon 25 Mar)
- ELIQUIS® (apixaban) Approved In Japan For The Prevention Of Stroke And Systemic Embolism In Patients With Nonvalvular Atrial FibrillationBusiness Wire(Wed 26 Dec)
- PropThink: Big Catalysts Approaching For Trius TherapeuticsACN Newswire(Thu 8 Nov)